Low Hepatitis C Reinfection Following Direct-Acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Direct acting antiviral (DAA) therapy is highly effective in PWID; however, rates, specific injection behaviors, and social determinants of drug use associated with HCV reinfection following DAA therapy among PWID on opioid agonist therapy (OAT) are poorly understood. PREVAIL was a randomized control trial that assessed models of HCV care for 150 PWID on OAT. Those who achieved SVR (n=141; 94%) were eligible for this extension study. Interviews and assessments of recurrent HCV viremia occurred at 6-month intervals for up to 24 months following PREVAIL. We used survival analysis to analyze variables associated with time to reinfection. Of 141 who achieved SVR, 114 had a least one visit in the extension study (62% male, mean age 52). Injection drug use (IDU) after SVR24 was reported in 19% (n=22). HCV reinfection was observed in three participants. Over 246 person-years of follow-up, the incidence of reinfection was 1.22/100 person-years (95% CI 0.25-3.57). All reinfections occurred among participants reporting ongoing IDU. The incidence of reinfection in participants reporting ongoing IDU (41 person-years of follow-up) was 7.4/100 person-years (95% CI 1.5-21.6). Reinfection was associated with reporting ongoing IDU in the follow-up period (p<.001), a lack confidence in the ability to avoid contracting HCV (p<.001), homelessness (p=.002), and living with a PWID (p=.007). HCV reinfection was low overall, but more common among people with ongoing IDU following DAA therapy on OAT, as well as those who were not confident in the ability to avoid contracting HCV, homeless, or living with a person who injects drugs. Interventions to mediate these risk factors following HCV therapy are warranted.